Guidance
Evidence-based recommendations on Sedaconda ACD‑S for sedation with volatile anaesthetics in intensive care.
Implementation
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
Next review: 2025
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice.
This guidance replaces NICE's medtech innovation briefing on AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229).